✦ LIBER ✦

Naloxone does not benefit levodopa-induced hallucinations in Parkinson's disease

✍ Scribed by R. Sandyk; M. A. Gillman

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 128 KB
Volume: 16
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410160616

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Does papaverine interact with levodopa i

Does papaverine interact with levodopa in Parkinson's disease?

✍ J. L. Montastruc; O. Rascol; J. Belin; M. Ane; A. Rascol 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

Accelerometric assessment of levodopa-in

Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease

✍ J.I. Hoff; A.A. v/d Plas; E.A.H. Wagemans; J.J. van Hilten 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

Our objective was to develop parameters for objective ambulatory measurements of levodopa-induced dyskinesias (LID) in patients with Parkinson's disease (PD). Twentythree PD patients with mild to severe LID were submitted to a standardized protocol of 1-minute recordings during rest, talking, stress

Polysomnographic sleep measures in Parki

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations

✍ Dr. Cynthia L. Comella; Caroline M. Tanner; Ruzica K. Ristanovic 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 1 views

Levodopa induces a cytoplasmic localizat

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease

✍ A. Di Rocco; P. Werner 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

Time course of loss of clinical benefit

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

✍ Robert A. Hauser; William C. Koller; Jean P. Hubble; Teresita Malapira; Karen Bu 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

DBH −1021C→T does not modify risk or age

DBH −1021C→T does not modify risk or age at onset in Parkinson's disease

✍ Lani S. Chun; Ali Samii; Carolyn M. Hutter; Alida Griffith; John W. Roberts; Ber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views